Assuming $5-7 sales price according to the current quarterly (all figure in USD).
Then looking at costs, we have,
2020 Vidalia update had costs at about $3/kg.
'Operating cost (all-in) is now estimated to be US$3,109/t being reduced from US$3,149/t estimated in the BFS'
From the 45kt DFS, it looks like $3/kg for Stage 2.
'Estimated all-in operating costs of US$3,023 per tonne (2023 real) for the 45ktpa AAM Vidalia facility, assuming Balama natural graphite cost is US$425 per tonne (FOB Nacala/Pemba) (2023 real)'
If everything goes smoothly to nameplate (it never does), below are very crude margins scenarios.
![]()
$72 million was the cash burn for the year. Food for thought. With a 45kt plant, seems like SYR would be in a good position even with todays depressed graphite prices. Assuming I didn't make any mistakes here (not very likely)
- Forums
- ASX - By Stock
- SYR
- Ann: December 2023 Quarterly Activities Presentation
SYR
syrah resources limited
Add to My Watchlist
1.96%
!
26.0¢

Ann: December 2023 Quarterly Activities Presentation, page-9
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
26.0¢ |
Change
0.005(1.96%) |
Mkt cap ! $270.9M |
Open | High | Low | Value | Volume |
25.5¢ | 27.3¢ | 25.5¢ | $634.3K | 2.391M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 379430 | 26.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
26.5¢ | 40672 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 370438 | 0.260 |
8 | 196397 | 0.255 |
13 | 317191 | 0.250 |
13 | 503263 | 0.245 |
20 | 837402 | 0.240 |
Price($) | Vol. | No. |
---|---|---|
0.265 | 838 | 1 |
0.270 | 102573 | 1 |
0.275 | 456506 | 8 |
0.280 | 167739 | 5 |
0.285 | 418600 | 6 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
SYR (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online